NutriKane D available here

Market Segments – Health

NutriKane D

The markets for MediKane products are vast, global, and growing.

The number of cases and the prevalence of high blood sugar levels have been steadily increasing over many decades. Research by the IDF shows that there are 463 million people with high blood sugar levels globally. The total estimate for people who are at risk of high blood sugar is 460 million. This is almost double the statistics from 1980. Factors driving this dramatic rise include lifestyle, food choices, excessive weight gain and obesity.


High blood sugar is now one of the top 10 causes of death globally.

BSLs was the direct cause of 4 million deaths in 2017, with a further 2.2 million deaths attributed to related conditions including cardiovascular and other diseases impacted by higher than optimal blood sugar levels.

On World Health Day 2016, the World Health Organisation (WHO) issued a call to action  drawing attention to the need to step up prevention and treatment of the condition globally.

In Australia, there are an estimated 1.2 million people are currently living with high blood sugar levels. There are also an additional 500,000 undiagnosed cases. The cost of treating these people in Australia is $14.6 billion p.a.

The national cost of these treatments in the USA was US$327 billion pa (2017).

High BSLs is the leading cause of preventable blindness in Australia.

There are more than 4,000 amputations every year in Australia.

There are no ‘blockbuster drugs on the horizon’, so treatment focuses on managing the blood sugar levels over the lifetime of those patients.

Pharmaceuticals are not yet a solution:

  • They cannot be taken by all patients (e.g. some medications cannot be used by patients with chronic kidney disease).
  • Their efficacy deteriorates over time due to habituation.
  • Many drugs can cause serious negative side effects.
  • Interventions become life critical when medicines and insulin injections cannot manage blood sugar levels.
  • Taking insulin is invasive. Insulin dosing is by injection as stomach acid will destroy it if taken orally.

Clinical trials have shown that NutriKane D has a positive impact on high BSLs. Using NutriKane D improves the efficacy of interventions and progression to secondary or tertiary stages becomes delayed or even prevented.

As a food product, NutriKane D has been approved for claims (by the Food Standards Australia New Zealand (FSANZ)) relating to the management of blood sugar levels.

MediKane’s key markets are the USA, China and India, and the table below shows the prevalence of high BSLs in these markets. When combined, these markets represent 50% of the potential global market.

All figures are in millions





















Source: IDF Atlas – Across the Globe

All figures are in millions

In summary:

  • In 2015, the IDF estimated that 422 million people had high BSLs – expected to increase to 642 million by 2040
  • The incidence is increasing in every country
  • 12% of global health expenditure is spent on the problem - US$673 billion
  • 1 in 7 births is affected by the Mother’s high BSL
  • 1 in 11 adults has high BSL globally
  • This is now a key UN health priority
  • No natural products proven to help before NutriKane D
  • No drug fully treats or cures the problem
  • 1 person dies from the condition every six seconds

    The table below shows the accessible markets as advised to MediKane by the IDF.  These initial markets are only a fraction of the potential markets in these countries but can be accessed in the near term. MediKane will target larger segments in each of these markets in future years.

    All figures are in millions



    Total Market

    Accessible Market
















     All figures are number of people

    The accessible market for NutriKane D is defined as people living with high BSLs, using oral drugs, looking for natural medications, can afford the product and who can access the product (i.e. good distribution networks and retail outlets); this represents approximately 60 million people worldwide.

    Of those 60 million people, MediKane is focused on the accessible markets in Australia and the USA in the short term, which together total 5.7 million people.

    In Australia, MediKane has been working closely with the ADEA to increase the awareness of the product and its efficacy. ADEA’s educators are champions of NutriKane D and are increasingly recommending NutriKane D to  people with high BSLs for superior, effective, all-natural management of the disease.

    The USA is the most significant market for all MediKane products. The market in the USA is lower than in both India and China. However due to superior healthcare services, superior infrastructure, ease of communicating with consumers and high average wealth, the USA is MediKane’s key market.

    That is the reason MediKane established a base office, and entity in the USA. MediKane USA LLC is an owned subsidiary, incorporated in Delaware with its office in Manhattan, New York, NY. Its CEO is a former Diabetes Australia executive, Michael Goldman.

    The IDF is expressing caution for people living in the COVID-19 environment: NutriKane has been shown to help  improve the health of the immune system.

    Older people and people with pre-existing medical conditions appear to be more vulnerable to becoming severely ill with the COVID-19 virus. When people with high BSLs develop a viral infection, it can be harder to treat due to fluctuations in blood glucose levels and, possibly, the presence of complications. There appear to be two reasons for this. Firstly, the immune system is compromised, making it harder to fight the virus and likely leading to a longer recovery period. Secondly, the virus may thrive in an environment of elevated blood glucose.